^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ACT-903

    i
    Other names: ACT-903, AFP + linker + maytansine
    Company:
    Alpha Cancer Technologies
    Drug class:
    Tubulin inhibitor, AFP-targeted antibody-drug conjugate
    Related drugs:
    1year
    High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. (PubMed, Cancer Cell Int)
    Studies were performed to investigate the use of recombinant human AFP (ACT-101) conjugated with maytansinoid toxins for targeted toxin delivery to cancer. No obvious signs of toxicity were seen in any of the treated groups. Observed efficacy and excellent tolerability of ACT-903 in these xenograft models support advancing the development of ACT-903 toward clinical use.
    Preclinical • Journal
    |
    AFP (Alpha-fetoprotein)
    |
    ACT-903